AMENDMENT, ASSIGNMENT, ASSUMPTION, NOVATION AND CONSENT AGREEMENTNovation and Consent Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS on October 6, 2004, Lorus Therapeutics Inc. (formerly 4325231 Canada Inc.) ("Old Lorus"), GeneSense Technologies Inc. ("GeneSense") and TEMIC entered into a subscription agreement providing for the issuance of three (3) five million dollar ($5,000,000) principal amount convertible debentures (each a "Debenture" and collectively, the "Debentures") on each of October 6, 2004, January 14, 2005 and April 15, 2005, each maturing on October 6, 2009;
AMENDMENT, ASSIGNMENT, ASSUMPTION, NOVATION AND CONSENT AGREEMENTNovation and Consent Agreement • September 27th, 2012 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS on October 6, 2004, Lorus Therapeutics Inc. (formerly 4325231 Canada Inc.) (“Old Lorus”), GeneSense Technologies Inc. (“GeneSense”) and TEMIC entered into a subscription agreement providing for the issuance of three (3) five million dollar ($5,000,000) principal amount convertible debentures (each a “Debenture” and collectively, the “Debentures”) on each of October 6, 2004, January 14, 2005 and April 15, 2005, each maturing on October 6, 2009;
AMENDMENT NO. 3 TONovation and Consent Agreement • July 5th, 2022
This Amendment No. 3 to Contract MA-017-19011637 ("Amendment No. r). is made and entered into as of the date fully executed by and between the County of Orange ("County''). a political subdivision of the State
